Drugs / INTERLEUKIN 15, RECOMBINANT NON-GLYCOSYLATED
INTERLEUKIN 15, RECOMBINANT NON-GLYCOSYLATED
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07410676 Background | Feb 2026 → Dec 2028 expected | breast cancer, colorectal cancer, cutaneous melanoma, esophageal cancer +9 | Essen Biotech | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INTERLEUKIN 15, RECOMBINANT NON-GLYCOSYLATED | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297989 ↗ |
| Known as | IL-15 | “Drug: Interleukin-15 (IL-15) Low-dose IL-15 given after NK cell infusion to support NK cell survival dose used in NK protocols: 6 MIU per dose” NCT07410676 ↗ |
| Known as | Interleukin-15 | “Drug: Interleukin-15 (IL-15) Low-dose IL-15 given after NK cell infusion to support NK cell survival dose used in NK protocols: 6 MIU per dose” NCT07410676 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297989 ↗ |